| Literature DB >> 34017936 |
Arun Sharma1, Sophia Matos1, Sandra L Ettema1, Stacie R Gregory1, Pardis Javadi1, Matthew D Johnson1, Brendan C Stack1, Dana L Crosby1.
Abstract
OBJECTIVE: To develop and assess an otolaryngology-specific surgical priority scoring system that incorporates varying levels of mucosal involvement. STUDYEntities:
Keywords: COVID-19; MeNTS; novel coronavirus; otolaryngology; surgical risk score
Year: 2021 PMID: 34017936 PMCID: PMC8114268 DOI: 10.1177/2473974X211012664
Source DB: PubMed Journal: OTO Open ISSN: 2473-974X
MeNTS Surgical Priority Score.
| Characteristic | Score | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| Patient factors | |||||
| Age, y | <20 | 20-40 | 41-50 | 51-65 | >65 |
| Lung disease (asthma, COPD, CF) | None | Minimal (rare inhaler) | >Minimal | ||
| Obstructive sleep apnea | Not present | Mild/moderate (on CPAP) | On CPAP | ||
| CV disease (HTN, CHF, CAD) | None | Minimal (no medications) | Mild (≤1 medication) | Moderate (2 medications) | Severe (≥3 medications) |
| Diabetes | None | Mild (no medications) | Moderate (PO medications only) | >Moderate (insulin) | |
| Immunocompromised[ | No | Moderate | Severe | ||
| ILI symptoms (fever, cough, sore throat, body aches, diarrhea) | None (asymptomatic) | Yes | |||
| Exposure to known COVID-19–positive person in past 14 days | No | Probably not | Possibly | Probably | Yes |
| Disease factors | |||||
| Nonoperative treatment option effectiveness | None available | Available, <40% as effective as surgery | Available, 40%-60% as effective as surgery | Available, 60%-95% as effective as surgery | Equally effective |
| Nonoperative treatment option resource/exposure risk | Significantly worse/not applicable | Somewhat worse | Equivalent | Somewhat better | Significantly better |
| Impact of 2-week delay on disease outcome | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Impact of 2-week delay on surgical difficulty/risk | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Impact of 6-week delay on disease outcome | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Impact of 6-week delay on surgical difficulty/risk | Significantly worse | Worse | Moderately worse | Slightly worse | No worse |
| Procedure factors | |||||
| OR time, min | ≤30 | 31-60 | 61-120 | 121-180 | >180 |
| Estimated length of stay | Outpatient | ≤23 h | 24-48 h | 48-72 h | ≥4 d |
| Postoperative ICU need, % | Very unlikely | <5 | 6-10 | 11-25 | >25 |
| Anticipated blood loss, cc | <100 | 100-250 | 251-500 | 501-750 | >750 |
| Surgical team size | 1 person | 2 people | 3 people | 4 people | >4 people |
| Intubation probability, % | <1 | 1-5 | 6-10 | 11-25 | >25 |
| Surgical site | ENT | ||||
Abbreviations: CAD, coronary artery disease; CF, cystic fibrosis; CHF, congestive heart failure; CPAP, continuous positive airway pressure; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CV, cardiovascular; ENT, ear, nose, and throat procedure; HTN, hypertension; ICU, intensive care unit; ILI, influenza-like illness; MeNTS, Medically Necessary, Time-Sensitive; OR, operating room; PO, per os.
Immunocompromised is defined as hematologic malignancy, stem cell transplant, solid organ transplant, active/recent cytotoxic chemotherapy, anti–tumor necrosis factor α or other immunosuppressants, >20 mg prednisone equivalent/d, congenital immunodeficiency, hypogammaglobulinemia on intravenous immunoglobulin (IVIG), and HIV with CD4 <200.
Mucosal Score.
| Score | Procedure | Example |
|---|---|---|
| 0 | No involvement of mucosa or airway secretions | Excision of scalp cancer |
| 5 | Middle ear or mastoid surgery | Mastoidectomy, ossicular chain reconstruction |
| 10 | Salivary gland surgery | Parotidectomy |
| 15 | Transoral or transnasal procedure (with possible aerosolization) without violation of mucosa | Rigid bronchoscopy |
| 20 | Transoral or open procedure with violation of mucosa | Tracheotomy, glossectomy, tonsillectomy |
| 25 | Transnasal or nasopharyngeal procedure with violation of mucosa, including all sinonasal and skull base procedures | Nasopharyngeal biopsy, adenoidectomy, endoscopic skull base resection |
Unique Components of the P-MeNTS Surgical Priority Score.
| Characteristic | Score | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| Patient factors | |||||
| Age, y | 16-18 | 6-15 | 1-5 | <1 | |
| Prematurity | Term: birth at 37 weeks GA or greater | Premature: birth at <37 weeks GA | |||
| Procedure factors | |||||
| Anticipated blood loss | <15% of blood volume | ≥15% of blood volume | |||
Abbreviations: ENT, ear, nose, and throat procedure; GA: gestational age; P-MeNTS: Pediatric Medically Necessary, Time-Sensitive.
Demographics and Surgical Priority Scores of All Adult Patients Scheduled for Surgery.
| Characteristic | All adult patients scheduled for surgery (n = 56) | Surgery cancelled (n = 46) | Surgery proceeded (n = 10) | |
|---|---|---|---|---|
| Age, median (IQR), y | 60 (50-68) | 59 (45-68) | 63 (55-78) | .210 |
| Sex, female, No. (%) | 26 (46) | 24 (52) | 2 (20) | .087 |
| ESAS tiers, No. (%) | <.001 | |||
| 1a | 13 (23) | 13 (28) | 0 | |
| 1b | 11 (20) | 11 (24) | 0 | |
| 2a | 11 (20) | 10 (22) | 1 (10) | |
| 2b | 6 (11) | 6 (13) | 0 | |
| 3a | 9 (16) | 3 (6.5) | 6 (60) | |
| 3b | 6 (11) | 3 (6.5) | 3 (30) | |
| MeNTS score, median (IQR) | 55 (52-60) | 56 (53-60) | 48 (41-54) | .004 |
| Mucosal score, median (IQR) | 20 (10-20) | 20 (5-25) | 20 (15-20) | .929 |
| MeNTS-M score, median (IQR) | 71.5 (60.5-80.5) | 74 (60-82) | 65.5 (61-72) | .171 |
Abbreviations: ESAS, Elective Surgery Acuity Scale; IQR, interquartile range; MeNTS, Medically Necessary, Time-Sensitive; MeNTS-M, Medically Necessary, Time-Sensitive–Mucosal.
Figure 1.Medically Necessary, Time-Sensitive (MeNTS) score, mucosal score, and MeNTS-Mucosal (MeNTS-M) score among adult patients, by whether surgery proceeded.
Demographics and Surgical Priority Scores of All Pediatric Patients Scheduled for Surgery.
| Characteristic | All pediatric patients scheduled for surgery (n = 49) | Surgery cancelled (n = 43) | Surgery proceeded (n = 6) | |
|---|---|---|---|---|
| Age, median (IQR), y | 3.3 (1.5-7.6) | 3.9 (1.7-7.9) | 0.9 (0.2-2.0) | .006 |
| Premature, No. (%) | 11 (22) | 7 (16) | 4 (67) | .018 |
| Sex, female, No. (%) | 26 (53) | 23 (53) | 3 (50) | 1.000 |
| ESAS tiers, No. (%) | <.001 | |||
| 1a | 38 (78) | 38 (88) | 0 | |
| 1b | 0 | 0 | 0 | |
| 2a | 5 (10) | 2 (9) | 1 (17) | |
| 2b | 0 | 0 | 0 | |
| 3a | 6 (12) | 1 (2) | 5 (83) | |
| 3b | 0 | 0 | 0 | |
| P-MeNTS score, median (IQR) | 54 (51-56) | 54 (51-56) | 55 (46-59) | .963 |
| Mucosal score, median (IQR) | 20 (5-25) | 20 (5-25) | 20 (15-20) | .407 |
| P-MeNTS-M score, median (IQR) | 74 (58-80) | 74 (56-80) | 70 (59-79) | .963 |
Abbreviations: ESAS, Elective Surgery Acuity Scale; IQR, interquartile range; P-MeNTS, Pediatric Medically Necessary, Time-Sensitive; P-MeNTS-M, Pediatric Medically Necessary, Time-Sensitive–Mucosal.
Figure 2.Pediatric Medically Necessary, Time-Sensitive (P-MeNTS) score, mucosal score, and Pediatric Medically Necessary, Time-Sensitive–Mucosal (P-MeNTS-M) score among pediatric patients, by whether surgery proceeded.
Correlation of Surgical Priority Scores With ESAS Tiers.[a]
| Adult patients | |||
|---|---|---|---|
| ESAS tiers | MeNTS | Mucosal | MeNTS-M |
| 1 (1a and 1b) | 56 (52.5-60) | 20 (15-25) | 77.5 (66-83) |
| 1a, 2a, 3a | 53 (49-55) | 20 (5-20) | 64 (58-73) |
| Pediatric patients[ | |||
| P-MeNTS | Mucosal | P-MeNTS-M | |
| 1 (1a and 1b) | 53 (51-55) | 20 (5-25) | 73.5 (56-80) |
Abbreviations: ESAS, Elective Surgery Acuity Scale; IQR, interquartile range; MeNTS, Medically Necessary, Time-Sensitive; MeNTS-M, Medically Necessary, Time-Sensitive–Mucosal; P-MeNTS, Pediatric Medically Necessary, Time-Sensitive; P-MeNTS-M, Pediatric Medically Necessary, Time-Sensitive–Mucosal.
All values shown are median (IQR).
No pediatric patients were in tier 1b, 2b, or 3b.
Comparison of Predictive Value of Surgical Priority Scoring Systems.
| Surgical priority scoring system | AUC | |
|---|---|---|
| Adult patients | ||
| MeNTS | 0.794 | Reference |
| Mucosal | 0.509 | .015 |
| MeNTS-M | 0.639 | .050 |
| Pediatric patients | ||
| P-MeNTS | 0.494 | Reference |
| Mucosal | 0.601 | .560 |
| P-MeNTS-M | 0.506 | .917 |
Abbreviations: AUC, area under the curve; MeNTS, Medically Necessary, Time-Sensitive; MeNTS-M, Medically Necessary, Time-Sensitive–Mucosal; P-MeNTS, Pediatric Medically Necessary, Time-Sensitive; P-MeNTS-M, Pediatric Medically Necessary, Time-Sensitive–Mucosal.